Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.93%
#3 Glidr Glidr +36.87%
#4 MowCat MowCat +27.93%
#5 Humanity Humanity +27.03%
#6 Codatta Codatta +18.91%
#7 Collector Crypt Collector Crypt +18.23%
#8 Walrus Walrus +18.21%
#9 Provenance Blockchain Provenance Blockchain +17.26%
#10 Enso Enso +16.84%
Coin of the day
EXOD EXOD
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Classement en actions #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Prix de l'action
$1.73
Dernière synchronisation: 2025-06-17
Capitalisation boursière
$2.55M
Changement (1 jour)
-0.29%
Changement (1 an)
0.00%
Pays
US
Échange Eiger BioPharmaceuticals, Inc. (EIGR)

Catégorie

Healthcare
Bénéfices pour Eiger BioPharmaceuticals, Inc. (EIGR)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Eiger BioPharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Eiger BioPharmaceuticals, Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE